Newsroom of

Levo Therapeutics, Inc.

Levo Therapeutics is dedicated to advancing treatments for Prader-Willi syndrome and related disorders.

Levo Therapeutics to License Exclusive Rights to Ferring Pharmaceuticals' Orphan-Designated Drug, Carbetocin, for the Treatment of Prader-Willi Syndrome

Levo Therapeutics, Inc. announced today that it has agreed to terms with Swiss-based Ferring Pharmaceuticals that, subject to contract, grant Levo Therapeutics worldwide rights to Ferring’s drug, carbetocin, for the treatment of Prader-Willi syndrome (PWS).  The agreement includes full data rights to the…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login